# Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

> **NCT01452607** · PHASE1 · COMPLETED · sponsor: **Sound Pharmaceuticals, Incorporated** · enrollment: 32 (actual)

## Conditions studied

- Hearing Loss
- Cancer

## Interventions

- **DRUG:** SPI-1005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01452607
- **Lead sponsor:** Sound Pharmaceuticals, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01452607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01452607, "Study to Evaluate the Safety and Pharmacokinetics of SPI-1005". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01452607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*